In vitro and in vivo preclinical evaluation of a minisphere emulsion-based formulation (SmPill®) of salmon calcitonin

被引:23
作者
Aguirre, Tanira A. S. [1 ,2 ,3 ]
Rosa, Monica [3 ]
Coulter, Ivan S. [3 ]
Brayden, David J. [1 ,2 ]
机构
[1] Univ Coll Dublin, UCD Sch Vet Med, Dublin 4, Ireland
[2] Univ Coll Dublin, UCD Conway Inst, Dublin 4, Ireland
[3] Dublin City Univ, Invent Ctr, Sigmoid Pharma, Dublin 9, Ireland
基金
爱尔兰科学基金会;
关键词
Salmon calcitonin; Oral bioavailability; Intestinal permeation enhancers; Oral peptide and protein delivery; Oil-in-water emulsions; DRUG-DELIVERY SYSTEMS; ORAL DELIVERY; PEPTIDE DELIVERY; ABSORPTION; BEADS; SCT; BIOAVAILABILITY; LIPOSOMES; DESIGN;
D O I
10.1016/j.ejps.2015.09.001
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Salmon calcitonin (sCT, MW3432 Da) is a benchmark molecule for an oral peptide delivery system because it is degraded and has low intestinal epithelial permeability. Four dry emulsion minisphere prototypes (SmPill (R)) containing sCT were co-formulated with permeation enhancers (PEs): sodium taurodeoxycholate (NaTDC), sodium caprate (C-10) or coco-glucoside (CG), or with a pH acidifier, citric acid (CA). Minispheres protected sCT from thermal degradation and the released sCT retained high bioactivity, as determined by cyclic AMP generation in T47D cells. Pre-minisphere emulsions of PEs combined with sCT increased absolute bioavailability (F) compared to native sCT following rat intra-jejunal (i.j.) and intra-colonic (i.c.) loop instillations, an effect that was more pronounced in colon. Minispheres corresponding to similar to 2000 I.U. (similar to 390 mu g) sCT/kg were instilled by i.j. or i.c. instillations and hypocalcaemia resulted from all prototypes. The absolute F (i.j.) of sCT was 11.0, 4.8, and 1.4% for minispheres containing NaTDC (10 mu mol/kg), CG (12 mu mol/kg) or CA (32 mu mol/kg) respectively. For i.c. instillations, the largest absolute F (22% in each case) was achieved for minispheres containing either C10 (284 mu mol/kg) or CG (12 mu mol/kg), whilst the absolute F was 8.2% for minispheres loaded with CA (32 mu mol/kg). In terms of relative F, the best data were obtained for minispheres containing NaTDC (i.j.), a 4-fold increase over sCT solution, and also for either C10 or CG (i.c.), where there was a 3-fold increase over sCT solution. Histology of instilled intestinal loops indicated that neither the minispheres nor components thereof caused major perturbation. In conclusion, selected SmPill (R) minisphere formulations may have the potential to be used as oral peptide delivery systems when delivered to jejunum or colon. (C) 2015 Elsevier B.V. All rights reserved.
引用
收藏
页码:102 / 111
页数:10
相关论文
共 51 条
[1]  
Aguirre T., 2013, THESIS U COLL DUBLIN
[2]   Investigation of coco-glucoside as a novel intestinal permeation enhancer in rat models [J].
Aguirre, Tanira A. S. ;
Rosa, Monica ;
Guterres, Silvia S. ;
Pohlmann, Adriana R. ;
Coulter, Ivan ;
Brayden, David J. .
EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS, 2014, 88 (03) :856-865
[3]   Absorption Enhancers: Applications and Advances [J].
Aungst, Bruce J. .
AAPS JOURNAL, 2012, 14 (01) :10-18
[4]   Chitosan beads for the delivery of salmon calcitonin: Preparation and release characteristics [J].
Aydin, Z ;
Akbuga, J .
INTERNATIONAL JOURNAL OF PHARMACEUTICS, 1996, 131 (01) :101-103
[5]   A phase 3 trial of the efficacy and safety of oral recombinant calcitonin: The oral calcitonin in postmenopausal osteoporosis (ORACAL) trial [J].
Binkley, Neil ;
Bolognese, Michael ;
Sidorowicz-Bialynicka, Anna ;
Vally, Tasneem ;
Trout, Richard ;
Miller, Colin ;
Buben, Christine E. ;
Gilligan, James P. ;
Krause, David S. .
JOURNAL OF BONE AND MINERAL RESEARCH, 2012, 27 (08) :1821-1829
[6]  
Carpenter John F, 2002, Pharm Biotechnol, V13, P109
[7]   In vitro and in vivo characterisation of a novel peptide delivery system: Amphiphilic polyelectrolyte-salmon calcitonin nanocomplexes [J].
Cheng, Woei-Ping ;
Thompson, Colin ;
Ryan, Sinead M. ;
Aguirre, Tanira ;
Tetley, Laurence ;
Brayden, David J. .
JOURNAL OF CONTROLLED RELEASE, 2010, 147 (02) :289-297
[8]  
Coulter I., 2010, Patent No. [US20100255087, 20100255087]
[9]  
Coulter I., 2010, Composition Comprising Oil Drops, Patent No. [WO2010/133609 A2, 2010133609]
[10]   Design and evaluation of solid lipid nanoparticles modified with peptide ligand for oral delivery of protein drugs [J].
Fan, Tingting ;
Chen, Chunhui ;
Guo, Han ;
Xu, Juan ;
Zhang, Jian ;
Zhu, Xi ;
Yang, Yang ;
Zhou, Zhou ;
Li, Lian ;
Huang, Yuan .
EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS, 2014, 88 (02) :518-528